Literature DB >> 27048398

Primary antiphospholipid syndrome, hypertrophic non-obstructive cardiomyopathy and hypotelorism.

Joerg Kellermair1, Juergen Kammler1, Peter Laubichler2, Clemens Steinwender1.   

Abstract

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with arterial/venous thrombosis. Cardiac manifestations of APS include valve stenosis/insufficiency, coronary artery disease and myocardial dysfunction presenting as dilated cardiomyopathy. In the following report, we present the case of a man with primary APS, hypertrophic non-obstructive cardiomyopathy and hypotelorism-a combination that has not yet been reported in the literature. 2016 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Year:  2016        PMID: 27048398      PMCID: PMC4840611          DOI: 10.1136/bcr-2016-214765

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  6 in total

1.  What do we know about the cardiac valve lesion in the antiphospholipid syndrome (APS)?

Authors:  M-C Amigo
Journal:  Lupus       Date:  2014-10       Impact factor: 2.911

Review 2.  Cardiac involvement in the antiphospholipid syndrome.

Authors:  F Tenedios; D Erkan; M D Lockshin
Journal:  Lupus       Date:  2005       Impact factor: 2.911

Review 3.  Antiphospholipid syndrome and the heart: a case series and literature review.

Authors:  Gentian Denas; Seema Padayattil Jose; Alessia Bracco; Giacomo Zoppellaro; Vittorio Pengo
Journal:  Autoimmun Rev       Date:  2014-11-12       Impact factor: 9.754

Review 4.  Catastrophic antiphospholipid syndrome: how to diagnose a rare but highly fatal disease.

Authors:  Cassyanne L Aguiar; Doruk Erkan
Journal:  Ther Adv Musculoskelet Dis       Date:  2013-12       Impact factor: 5.346

5.  2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).

Authors:  Perry M Elliott; Aris Anastasakis; Michael A Borger; Martin Borggrefe; Franco Cecchi; Philippe Charron; Albert Alain Hagege; Antoine Lafont; Giuseppe Limongelli; Heiko Mahrholdt; William J McKenna; Jens Mogensen; Petros Nihoyannopoulos; Stefano Nistri; Petronella G Pieper; Burkert Pieske; Claudio Rapezzi; Frans H Rutten; Christoph Tillmanns; Hugh Watkins
Journal:  Eur Heart J       Date:  2014-08-29       Impact factor: 29.983

Review 6.  Dilated cardiomyopathy due to thrombotic microangiopathy as the only manifestation of antiphospholipid syndrome: a case report.

Authors:  F Vaccaro; D Caccavo; E Roumpedaki; G De Vincentis; C R T Di Gioia; P Gallo; P Palange
Journal:  Int J Immunopathol Pharmacol       Date:  2008 Jan-Mar       Impact factor: 3.219

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.